Information MCC950 MCC950 is a potent and selective inhibitor of NLRP3 with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively. Targets NLRP3 (BMDM-based assay); NLRP3 (HMDM-based assay) 7.5 nM; 8.1 nM In vitro MCC950 is a potent, selective, small molecule inhibitor of NLRP3. MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. MCC950 is active in ex vivo samples from individuals with Muckle-Wells syndrome. MCC950 reduces Interleukin-1p (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescues neonatal lethality in a mouse model of CAPS. Cell Research(from reference) Cell lines：BMDM, HMDM, PBMC, HEK293T cells Concentrations：0.001 μM–10 μM, 5 nM–1000 nM Incubation Time：30 min, 45 min